Document is current
Any future updates will be listed below
-
Authors
Shi, Joy https://orcid.org/0000-0002-4234-7999
Løberg, Magnus
Kalager, Mette
Wieszczy, Paulina
Pilonis, Nastazja D.
Adami, Hans-Olov
Kaminski, Michal F.
Bretthauer, Michael
Hernán, Miguel A.
,
Emilsson, Louise
-
Funding
Funding for this research was provided by:
Nordic Cancer Union
Norges Forskningsråd (197309)
Kreftforeningen
Helse Sør-Øst RHF (5135)
Narodowe Centrum Badań i Rozwoju (N R13 0024 04)
Polish-Norwegian Research Programme (Pol-Nor/204233/30/2013)
Medical Center for Postgraduate Education, Poland (501-1-09-12-12/22)
Polska Fundacja Gastroenterologii
The Dutch Ministry of Health and Health Care Prevention (ZonMw 2008)
ZonMw (120720012)
Centre for Translational Molecular Medicine
Swedish Cancer Foundation (2010/345, CAN 2013/553)
Regionala Forskningsrådet Uppsala/Örebro (2368/10-221)
AFA Försäkring (130072)
- License Information
-
More Information
Article History
Received: 6 May 2023
Accepted: 12 February 2025
First Online: 25 April 2025
Declarations
:
: Joy Shi, Magnus Løberg, Mette Kalager, Paulina Wieszczy, Nastazja D. Pilonis, Hans-Olov Adami, Louise Emilsson, Kjetil Garborg, Maciej Rupinski, Øyvind Holme, Andrzej Mroz, Ernst J. Kuipers, and Geir Hoff declare they have no financial interest. Michal F. Kaminski has received speaker and consultant honoraria from Alfasigma USA, Inc., Boston Scientific Corporation, Fujifilm Corporation and Olympus. Michael Bretthauer has served as an expert witness for Cybernet Systems Co., Ldt. and Paion. Miguel Hernán is a consultant to ProPublica and Adigens Health, a company of which he owns equity, and a member of ADIA Lab's Advisory Board. Evelien Dekker has received speaker and consultant honoraria from Ambu, Fujifilm Medical Systems USA, Inc., GI Supply, Inc., Ipsen Biopharm Limited, Norgine, Olympus Corporation and Paion. Manon Spaander has received additional research support from Medtronic, Norgine, Sentinel and Sysmex Inostics Inc. Ann G. Zauber has received consultant honoraria from the American Cancer Society. Jaroslaw Regula has received speaking honoraria from Ipsen Pharma SAS and has served as a member of a Scientific Advisory Board for Olympus.
: This study was performed in line with the principles of the Declaration of Helsinki. The trial was approved by ethics committees of all participating centers, the Swedish National Council on Medical Ethics, and the Health Council of the Netherlands [].
: The authors affirm that all participants who underwent colonoscopy screening provided informed consent for publication of the data that was collected and analyzed from the Nordic-European Initiative on Colorectal Cancer (NordICC) randomized trial.
: Given the pragmatic design of the trial, participants underwent randomization before being asked to participate in the trial (in the invited group) or not asked to participate (the usual-care group). Informed consent was obtained for all participants who underwent colonoscopy screening.
